GlassScriptPhysician profile
Edward Horton
NPI 1609302942
$4,175.48
in general payments reported to CMS, 2019-2025
12 companies · $1,012 in 2025
The $1,012 reported for 2025 was more than what 88% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $232 · 2023: $211 · 2024: $2,721 · 2025: $1,012.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,481 · Travel and Lodging: $1,372 · Education: $90.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,480.53 |
| Travel and Lodging | $1,372.33 |
| Education | $90.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,457.02 | 2024-2025 | Accolade Sr, General - Therapies |
| Medtronic, INC. | $695.32 | 2022-2025 | Aurora Ev-Icd Mri Surescan, Linq II, Azure Xt Dr Mri Surescan |
| Biosense Webster, INC. | $506.84 | 2024-2025 | Carto 3 |
| Amgen INC. | $116.93 | 2022-2023 | Repatha |
| Merck Sharp & Dohme LLC | $97.33 | 2023 | Verquvo |
| Actelion Pharmaceuticals US, INC. | $92.33 | 2024 | Uptravi |
| Abbott Laboratories | $83.08 | 2022-2023 | Gallant, Assurity |
| Abiomed | $38.21 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $28.91 | 2023 | Camzyos |
| Cardiovascular Systems INC. | $24.32 | 2022 | |
| Novo Nordisk INC | $21.67 | 2024 | Wegovy |
| Terumo Medical Corporation | $13.52 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Horton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.